EMA Withdrawn: Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) — Sandoz GmbH

View source ↗

Summary

The European Medicines Agency has withdrawn Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) from the European market. It was indicated for non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Sandoz GmbH. Decision date: 04/09/2024